$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414068739 Filed on November 14, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2014 Q2
Revenue	$1.066M	$1.042M	$949.5K
YoY Change	-1.83%	-0.74%	-23.43%
Cost Of Revenue	$1.104M	$1.097M	$1.090M
YoY Change	-1.41%	-2.69%	-0.91%
Gross Profit	-$37.96K	-$54.80K	-$136.2K
YoY Change	11.97%	-29.11%	-197.26%
Gross Profit Margin	-3.56%	-5.26%	-14.34%
Selling, General & Admin	$841.7K	$929.7K	$990.0K
YoY Change	0.15%	-7.97%	1.02%
% of Gross Profit
Research & Development	$140.6K	$176.6K	$200.0K
YoY Change	-17.29%	20.15%	11.11%
% of Gross Profit
Depreciation & Amortization	$135.2K	$170.0K	$180.0K
YoY Change	-24.9%	-10.54%	-5.26%
% of Gross Profit
Operating Expenses	$982.4K	$1.106M	$1.180M
YoY Change	-2.78%	-4.4%	1.72%
Operating Profit	-$1.020M	-$1.161M	-$1.316M
YoY Change	-2.3%	-5.95%	29.04%
Interest Expense	$0.00	$3.451K	-$360.0K
YoY Change	-100.0%	365.72%	-1300.0%
% of Operating Profit
Other Income/Expense, Net	$113.4K	$375.2K
YoY Change	-3.44%	-1131.26%
Pretax Income	-$910.0K	-$790.0K	-$1.680M
YoY Change	-2.15%	-37.8%	69.7%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$907.0K	-$785.9K	-$1.678M
YoY Change	-2.16%	-38.17%	69.48%
Net Earnings / Revenue	-85.11%	-75.41%	-176.7%
Basic Earnings Per Share
Diluted Earnings Per Share	-$16.58K	-$14.40K	-$31.03K
COMMON SHARES
Basic Shares Outstanding	54.87M shares	54.88M shares	54.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.38M	$12.10M	$17.68M
YoY Change	158.05%	129.17%	509.66%
Cash & Equivalents	$1.337M	$2.075M	$7.680M
Short-Term Investments	$10.05M	$10.03M	$10.00M
Other Short-Term Assets	$220.0K	$250.0K	$26.69K
YoY Change	37.5%	19.05%	0.0%
Inventory	$411.4K	$407.5K	$359.7K
Prepaid Expenses
Receivables	$797.4K	$962.3K	$913.0K
Other Receivables	$10.98K	$5.258K	$53.08K
Total Short-Term Assets	$12.83M	$13.73M	$19.21M
YoY Change	116.47%	98.89%	332.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$761.4K	$855.4K	$1.018M
YoY Change	-43.58%	-43.35%	-39.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.10M	$10.05M	$5.400M
YoY Change
Other Assets	$250.9K	$258.6K	$264.1K
YoY Change	-4.49%	-4.7%	-4.5%
Total Long-Term Assets	$11.76M	$11.81M	$7.334M
YoY Change	419.64%	385.61%	180.83%
TOTAL ASSETS
Total Short-Term Assets	$12.83M	$13.73M	$19.21M
Total Long-Term Assets	$11.76M	$11.81M	$7.334M
Total Assets	$24.59M	$25.54M	$26.55M
YoY Change	200.27%	173.6%	276.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$490.0K	$510.0K	$570.0K
YoY Change	13.95%	-21.54%	32.56%
Accrued Expenses	$450.0K	$470.0K	$580.0K
YoY Change	7.14%	46.88%	61.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$941.9K	$979.1K	$1.154M
YoY Change	11.17%	0.94%	45.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.120M	$1.140M	$1.440M
YoY Change	31.76%	20.0%	60.0%
Total Long-Term Liabilities	$1.120M	$1.140M	$1.440M
YoY Change	31.76%	20.0%	60.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$941.9K	$979.1K	$1.154M
Total Long-Term Liabilities	$1.120M	$1.140M	$1.440M
Total Liabilities	$2.057M	$2.115M	$2.593M
YoY Change	21.09%	10.16%	53.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.74M	-$58.84M	-$58.05M
YoY Change	10.05%	10.26%	11.44%
Common Stock	$54.88K	$54.88K	$54.70K
YoY Change	42.85%	42.85%	58.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.390K	$8.390K	$8.390K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	13.20K shares	13.20K shares	13.20K shares
Shareholders Equity	$22.53M	$23.42M	$23.96M
YoY Change
Total Liabilities & Shareholders Equity	$24.59M	$25.54M	$26.55M
YoY Change	200.27%	173.6%	276.3%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2014 Q2
OPERATING ACTIVITIES
Net Income	-$907.0K	-$785.9K	-$1.678M
YoY Change	-2.16%	-38.17%	69.48%
Depreciation, Depletion And Amortization	$135.2K	$170.0K	$180.0K
YoY Change	-24.9%	-10.54%	-5.26%
Cash From Operating Activities	-$620.0K	-$1.140M	-$990.0K
YoY Change	-27.06%	27.8%	25.32%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$7.453K	-$20.00K
YoY Change	100.0%	265.16%
Acquisitions
YoY Change
Other Investing Activities	-$70.00K	-$4.670M	-$15.40M
YoY Change
Cash From Investing Activities	-$110.0K	-$4.680M	-$15.42M
YoY Change	450.0%	100958.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	220.0K	390.0K
YoY Change	0.0%	-93.29%	3800.0%
NET CHANGE
Cash From Operating Activities	-620.0K	-1.140M	-990.0K
Cash From Investing Activities	-110.0K	-4.680M	-15.42M
Cash From Financing Activities	-10.00K	220.0K	390.0K
Net Change In Cash	-740.0K	-5.600M	-16.02M
YoY Change	-15.91%	-334.88%	1953.85%
FREE CASH FLOW
Cash From Operating Activities	-$620.0K	-$1.140M	-$990.0K
Capital Expenditures	-$40.00K	$7.453K	-$20.00K
Free Cash Flow	-$580.0K	-$1.147M	-$970.0K
YoY Change	-30.12%	28.34%	22.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54870596	shares
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54701708	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54883445	shares
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	23424045	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25539315	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26549255	USD
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	27286	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	38607	USD
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82213811	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81959853	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58836318	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58050456	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	54883	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	54702	USD
CY2014Q3	us-gaap	Liabilities Liabilities	2115270	USD
CY2014Q2	us-gaap	Liabilities Liabilities	2593487	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	979066	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1153927	USD
CY2014Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	250000	USD
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	573000	USD
CY2014Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	886204	USD
CY2014Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	866560	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94462	USD
CY2014Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	10046537	USD
CY2014Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	5401398	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	407479	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	359737	USD
CY2014Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5258	USD
CY2014Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	53082	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	80433	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181221	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181208	USD
CY2014Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	252183	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	206047	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2075317	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7680073	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	10025267	USD
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	153592	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	141592	USD
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	105503	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	236282	USD
CY2014Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	115821	USD
CY2014Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	120765	USD
CY2014Q3	us-gaap	Assets Assets	25539315	USD
CY2014Q2	us-gaap	Assets Assets	26549255	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	509688	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	574855	USD
CY2014Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258638	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	264076	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	13727763	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	19214900	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855398	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1017915	USD
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	10002912	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	962259	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	913049	USD
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54701708	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54883445	shares
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1042101	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1049915	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1096903	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1127223	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	-54802	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	-77308	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1999942	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54868053	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35921712	shares
CY2014Q3	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium		USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-785862	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1270906	USD
CY2014Q3	isr	Noncash Investing And Financing Items NoncashInvestingAndFinancingItems	-17000	USD
CY2013Q3	isr	Noncash Investing And Financing Items NoncashInvestingAndFinancingItems	-726378	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5284163	USD
CY2014Q3	isr	Noncash Investing And Financing Item Deemed Preferred Stock Dividend NoncashInvestingAndFinancingItemDeemedPreferredStockDividend		USD
CY2013Q3	isr	Noncash Investing And Financing Item Deemed Preferred Stock Dividend NoncashInvestingAndFinancingItemDeemedPreferredStockDividend	726378	USD
CY2014Q3	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	17000	USD
CY2013Q3	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification		USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	215686	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3280888	USD
CY2013Q3	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	726378	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-788520	USD
CY2014Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	306000	USD
CY2013Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-36000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	3451	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	741	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	375244	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36387	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	1106304	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1157211	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1161106	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1234519	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	72695	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	354	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	176610	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	146990	USD
CY2014Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	353743	USD
CY2013Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	359185	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	575951	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	651036	USD
CY2014Q3	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	11321	USD
CY2013Q3	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	5001	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	169970	USD
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	176314	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5604756	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2384236	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2899927	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1801457	USD
CY2014Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70411	USD
CY2013Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
CY2014Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145275	USD
CY2013Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD
CY2014Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	13	USD
CY2013Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	18	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4677256	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4631	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1479431	USD
CY2014Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2296	USD
CY2013Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2572	USD
CY2014Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	22355	USD
CY2013Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		USD
CY2013Q3	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2209	USD
CY2014Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	46136	USD
CY2013Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7524	USD
CY2014Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-65167	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	220824	USD
CY2013Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-16999	USD
CY2014Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	12000	USD
CY2013Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	12000	USD
CY2014Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-130779	USD
CY2013Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-42486	USD
CY2014Q3	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-47824	USD
CY2014Q3	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	4645139	USD
CY2013Q3	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		USD
CY2014Q3	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-4944	USD
CY2013Q3	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	3698	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1143186	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-892021	USD
CY2014Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7453	USD
CY2013Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2041	USD
CY2014Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	14029	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	21453	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	38353	USD
CY2014Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37889	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33475	USD
CY2014Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47742	USD
CY2013Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30673	USD
CY2014Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7734	USD
CY2013Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7685	USD
CY2014Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	19644	USD
CY2013Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17960	USD
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2014Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	34999	USD
CY2014Q3	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 0;"> <tr style=" vertical-align: top; text-align: justify;"> <td style=" width: 0in; border-left: none; border-right: none; border-top: none; border-bottom: none;"> </td> <td width="24px" style=" text-align: left; border: none; font-family : Times New Roman;"><strong>2.</strong></td> <td style=" text-align: justify; padding-left: 0.25in; font-family : Times New Roman; border-left: none; border-right: none; border-top: none; border-bottom: none;"><strong>New Accounting Pronouncements</strong></td> </tr> </table> </div> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <div style=" display: inline; font-size: 13px; font-family : Times New Roman; font-variant: normal; font-weight: normal; font-style: normal; text-decoration: none; color: rgb(0, 0, 0);"> <p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;"><font style=" background-color: white;">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.  </font></p> <p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background-color: white;"> </p> <p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background-color: white;"><font style=" background-color: white;">In August 2014, the FASB issued ASU No. 2014-15Presentation of Financial StatementsGoing Concern.   The guidance requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable).  If conditions or events exist that raise substantial doubt about an entity's ability to continue as a going concern, the guidance requires disclosure in the financial statements.   The guidance will be effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></p> </div> </div> </div>
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2636497	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13156389	shares
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	189768	USD
CY2014Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	173417	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	173996	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	151321	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	43715	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y6M7D
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M24D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0177	pure
CY2014Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	133564	shares
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M12D
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y4M10D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0185	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.59
CY2013Q3	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	6906	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.59
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3231	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	65000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.58
CY2013Q3	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	25150	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.58
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3231	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.15
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	774655	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2112233	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.07
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	319044	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	252308	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.05
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	933618	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	896932	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1760312	shares
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21453	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38353	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2180858	shares
CY2014Q3	isr	Percentage Of Royalty Rate Payable PercentageOfRoyaltyRatePayable	0.01	pure
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	396574	shares
CY2014Q3	isr	Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares	48173	shares
CY2014Q3	isr	Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights	1.45
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.22
CY2014Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	250000	USD
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	140000	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	444747	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.43
CY2013Q3	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	726378	USD
CY2014Q3	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
CY2014Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2014Q3	dei	Document Type DocumentType	10-Q
CY2014Q3	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
CY2014Q3	dei	Amendment Flag AmendmentFlag	false
CY2014Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2013Q3	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	184514	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	48500	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	6045	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3279292	USD
CY2013Q3	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	4120	USD
CY2013Q3	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	3000	USD
CY2014Q3	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	isr	Gross Proceeds From Issuance Of Stock GrossProceedsFromIssuanceOfStock	3703527	USD
CY2013Q3	isr	Payments For Underwriting Fees Costs PaymentsForUnderwritingFeesCosts	185176	USD
CY2014Q3	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	3000	USD
CY2014Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2014Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1

Files In Submission

Name	View Source	Status
0001144204-14-068739-index-headers.html	Edgar Link	pending
0001144204-14-068739-index.html	Edgar Link	pending
0001144204-14-068739.txt	Edgar Link	pending
0001144204-14-068739-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isr-20140930.xml	Edgar Link	completed
isr-20140930.xsd	Edgar Link	pending
isr-20140930_cal.xml	Edgar Link	unprocessable
isr-20140930_def.xml	Edgar Link	unprocessable
isr-20140930_lab.xml	Edgar Link	unprocessable
isr-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v393624_10q.htm	Edgar Link	pending
v393624_ex31-1.htm	Edgar Link	pending
v393624_ex31-2.htm	Edgar Link	pending
v393624_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2014 Q4 Form 10-Q Financial Statement

#000114420414068739 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2014 Q4 Form 10-Q Financial Statement

#000114420414068739 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx